Cost-effectiveness of RAS screening before monoclonal antibodies therapy in metastatic colorectal cancer based on FIRE3 Study

The surprising results published by FIRE-3 revealed that the overall survival (OS) of RAS wild-type metastatic colorectal cancer (mCRC) patients treated with Cetuximab(Cmab) and FOLFIRI combination was prolonged to 33.1 months. The substantial increase in testing and treatment costs, however, impose...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancer Biol Ther
Autori principali: Wen, Feng, Yang, Yu, Zhang, Pengfei, Zhang, Jian, Zhou, Jing, Tang, Ruilei, Chen, Hongdou, Zheng, Hanrui, Fu, Ping, Li, Qiu
Natura: Artigo
Lingua:Inglês
Pubblicazione: Taylor & Francis 2015
Soggetti:
Clinical Study
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4846122/
https://ncbi.nlm.nih.gov/pubmed/26418570
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384047.2015.1095398
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi